Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial
Di Wu,Jing Li,Dong Xu,Joan T Merrill,Ronald F van Vollenhoven,Yi Liu,Jiankang Hu,Yang Li,Fen Li,Chenghui Huang,Guochun Wang,Xiaomei Li,Jianhong Zhao,Dongbao Zhao,Cibo Huang,Huaxiang Liu,Wei Wei,Guixiu Shi,Fuai Lu,Xiaoxia Zuo,Liqi Bi,Zhijun Li,Xiaoxia Wang,Miaojia Zhang,Ning Tie,Juan Li,Hanyou Mo,Jianmin Fang,Chunde Bao,Fengchun Zhang
DOI: https://doi.org/10.1136/ard-2023-224854
2024-03-12
Abstract:Objectives: This phase 2b, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of telitacicept, a novel fusion protein that neutralises signals of B lymphocyte stimulator and a proliferation-inducing ligand, in active systemic lupus erythematosus (SLE). Methods: Adult patients with active SLE (n=249) were recruited from 29 hospitals in China and randomised 1:1:1:1 to receive subcutaneous telitacicept at 80 mg (n=62), 160 mg (n=63), 240 mg (n=62) or placebo (n=62) once weekly in addition to standard therapy. The primary endpoint was the proportion of patients achieving an SLE Responder Index 4 (SRI-4) response at week 48. Missing data were imputed using the last observation carried forward method. Results: At week 48, the proportion of patients achieving an SRI-4 response was 75.8% in the 240 mg telitacicept group, 68.3% in the 160 mg group, 71.0% in the 80 mg group and 33.9% in the placebo group (all p<0.001). Significant treatment responses were observed in secondary endpoints, including a ≥4-point reduction on the Systemic Lupus Erythematosus Disease Activity Index, a lack of Physician's Global Assessment score worsening and a glucocorticoid dose reduction in the 240 mg group. Telitacicept was well tolerated, and the incidence of adverse events and serious adverse events was similar between the telitacicept and placebo groups. Conclusions: This phase 2b clinical trial met the primary endpoint. All telitacicept groups showed a significantly higher proportion of patients achieving an SRI-4 response than the placebo group at week 48, and all doses were well tolerated. These results support further investigations of telitacicept in clinical trials involving more diverse populations and larger sample sizes. Trial registration number: ClinicalTrials.gov Registry (NCT02885610).